Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide decanoate in pediatric heterozygous familial hypercholesterolemia
jRCT2040260089Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Enlicitide decanoate with Placebo (2 arms). Primary endpoints: Maximum plasma concentration of enlicitide, Area under the concentration-time curve from 0 to 24 hours of enlicitide and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on jRCT2040260089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2040260089.